BJ
CARM

BlackRock Japan’s Carisma Therapeutics CARM Stock Holding History

BlackRock Japan’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-73
Closed -$4K – 1280
2015
Q2 		$4K Sell
73
-140
-66% -$19.8K ﹤0.01% 1316
2015
Q1 		$38K Buy
+213
New +$46.5K ﹤0.01% 1113

Other funds holding CARM

TRV
Third Rock Ventures Boston, Massachusetts $1.07B AUM 170.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
FV2GP
Flagship Ventures 2007 General Partner Cambridge, Massachusetts $107M AUM
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
Rotella Capital Management Bellevue, Washington $1.47M AUM 12.32% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BlackRock Japan's CARM Position: Q3 2015 in Review

BlackRock Japan sold out of Carisma Therapeutics (CARM) in Q3 2015, closing a stake of 73 shares — an estimated $4K sold.

BlackRock Japan first reported a position in CARM in Q1 2015 and held it in 2 quarters. The position peaked at $38K in Q1 2015. 30 funds tracked by Wall St. Rank hold CARM as of Q3 2015.

  • BlackRock Japan reported no remaining Carisma Therapeutics position as of Q3 2015 after selling out during the quarter.
  • BlackRock Japan sold 73 Carisma Therapeutics shares in Q3 2015, an estimated $4K.
  • BlackRock Japan first reported a position in Carisma Therapeutics in Q1 2015 and held it in 2 quarters.
  • BlackRock Japan's Carisma Therapeutics position peaked at $38K in Q1 2015.
  • 30 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q3 2015.

Based on BlackRock Japan's 13F filing for Q3 2015, filed 13 Nov 2015.